|
Video: What is a Stock Split?
|
|
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea. According to our Jazz Pharmaceuticals stock split history records, Jazz Pharmaceuticals has had 0 splits. | |
|
Jazz Pharmaceuticals (JAZZ) has 0 splits in our Jazz Pharmaceuticals stock split history database.
Looking at the Jazz Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Jazz Pharmaceuticals shares, starting with a $10,000 purchase of JAZZ, presented on a split-history-adjusted basis factoring in the complete Jazz Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$139.78 |
|
End price/share: |
$120.42 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-13.85% |
|
Average Annual Total Return: |
-1.48% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,615.13 |
|
Years: |
10.00 |
|
|
|
|
|